吡非尼酮和尼達尼布在新型冠狀病毒感染后肺纖維化中的應用進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

YANG ying ¹ , XU Kaifeng ² ,  WEI Lijuan ¹

1. ;
2. ;

Corresponding?author：

WEI Lijuan, Email: weilijuan541@sina.com

Keywords：

DOI：

10.7507/1671-6205.202311018

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： YANG ying, XU Kaifeng, WEI Lijuan. 吡非尼酮和尼達尼布在新型冠狀病毒感染后肺纖維化中的應用進展. Chinese Journal of Respiratory and Critical Care Medicine, 2024, 23(8): 593-598. doi: 10.7507/1671-6205.202311018 Copy

1.	World Health Organization. WHO coronavirus (COVID-19) dashboard[EB/OL]. [2021-12-04]. http://covid19.who.int.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.	Tanni SE, Fabro AT, de Albuquerque A, et al. Pulmonary fibrosis secondary to COVID-19: a narrative review. Expert Rev Respir Med. 2021 Jun;15(6): 791-803.
14.
15.
16.
17.
18.
19.
20.
21.	McDonald LT. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol, 2021, 320(2): L257-L265.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.	Kerget B, Cil G, Araz O, et al. When and how important is anti-fibrotic therapy in the post-COVID-19 period? Bratisl Lek Listy, 2022, 123(9): 6953-6958.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.

1. World Health Organization. WHO coronavirus (COVID-19) dashboard[EB/OL]. [2021-12-04]. http://covid19.who.int.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13. Tanni SE, Fabro AT, de Albuquerque A, et al. Pulmonary fibrosis secondary to COVID-19: a narrative review. Expert Rev Respir Med. 2021 Jun;15(6): 791-803.
14.
15.
16.
17.
18.
19.
20.
21. McDonald LT. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol, 2021, 320(2): L257-L265.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51. Kerget B, Cil G, Araz O, et al. When and how important is anti-fibrotic therapy in the post-COVID-19 period? Bratisl Lek Listy, 2022, 123(9): 6953-6958.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.

Previous Article
生物標志物對ARDS預后的評估
Next Article
呼出氣揮發性有機物在呼吸系統非感染性疾病中的應用

Chinese Journal of Respiratory and Critical Care Medicine

吡非尼酮和尼達尼布在新型冠狀病毒感染后肺纖維化中的應用進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content